ABSTRACT

Background: Despite recent advances in the understanding of the molecular landscape of biliary tract cancer (BTC), advanced disease continues to carry a poor prognosis, and the benefit from systemic treatments remains modest. However, BTCs have emerged as malignancies harboring specific potentially druggable aberrations, and thus, several molecularly targeted treatments have been recently tested. Among these, fibroblast growth factor receptor (FGFR) inhibitors have shown interesting results in previously treated BTC patients with advanced disease

Areas covered: In this review, we aimed to provide an overview of available evidence on FGFR inhibitors in elderly patients with metastatic BTC, especially focusing on subgroup analyses of recently published trials exploring this novel therapeutic approach in these aggressive malignancies.

Expert opinion: The FGFR1, FGFR2, and FGFR3 inhibitor pemigatinib has been recently approved by the United States Food and Drug Administration (FDA) in metastatic BTCs harboring FGFR2 fusion or other rearrangement. However, few data are available regarding the use of FGFR inhibitors in elderly BTCs, a patient population that remains seriously under-represented in clinical trials.

摘要

背景：尽管最近在对胆道癌 (BTC) 分子景观的理解方面取得了进展，但晚期疾病的预后仍然很差，全身治疗的益处仍然不大。然而，BTC 已成为具有特定潜在药物畸变的恶性肿瘤，因此，最近测试了几种分子靶向治疗。其中，成纤维细胞生长因子受体 (FGFR) 抑制剂在先前接受过治疗的晚期疾病 BTC 患者中显示出有趣的结果

涵盖的领域：在这篇综述中，我们旨在提供关于老年转移性 BTC 患者 FGFR 抑制剂的可用证据的概述，特别关注最近发表的试验的亚组分析，这些试验探索了这种针对这些侵袭性恶性肿瘤的新型治疗方法。

专家意见： FGFR1、FGFR2 和 FGFR3 抑制剂 pemigatinib 最近已被美国食品和药物管理局 (FDA) 批准用于携带 FGFR2 融合或其他重排的转移性 BTC。然而，关于在老年 BTC 中使用 FGFR 抑制剂的数据很少，这一患者群体在临床试验中仍然严重不足。